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Summary
The “BH3-only” proteins of the BCL-2 family require “multidomain” proapoptotic members BAX and BAK to release
cytochrome c from mitochondria and kill cells. We find short peptides representing the -helical BH3 domains of BID or
BIM are capable of inducing oligomerization of BAK and BAX to release cytochrome c. Another subset characterized by
the BH3 peptides from BAD and BIK cannot directly activate BAX, BAK but instead binds antiapoptotic BCL-2, resulting
in the displacement of BID-like BH3 domains that initiate mitochondrial dysfunction. Transduced BAD-like and BID-like
BH3 peptides also displayed synergy in killing leukemic cells. These data support a two-class model for BH3 domains:
BID-like domains that “activate” BAX, BAK and BAD-like domains that “sensitize” by occupying the pocket of antiapoptotic
members.
Introduction BAX, which is located in the cytosol or loosely attached to
membranes, inserts deeply into the outer mitochondrial mem-
brane as a homooligomerized multimer (Eskes et al., 2000;Diverse intrinsic death signals emanating from multiple subcellu-
lar locales all induce the release of cytochrome c from mitochon- Gross et al., 1998; Wolter et al., 1997). Inactive BAK resides at
the mitochondrion, where it also undergoes an allosteric confor-dria to activate Apaf-1 and result in effector caspase activation.
Proteins in the BCL-2 family are major regulators of the commit- mational change in response to death signals, which includes
homooligomerization (Griffiths et al., 1999; Wei et al., 2000).ment to programmed cell death as well as executioners of death
signals at the mitochondrion. Members of this family include Cells deficient in both BAX and BAK are resistant to a wide
variety of death stimuli that emanate from multiple locationsboth pro- and antiapoptotic proteins and share homology in up
to four conserved regions termed BCL-2 homology (BH) 1–4 within the cell (Wei et al., 2001).
The BH3-only molecules constitute the third subset of thisdomains (Adams and Cory, 1998). The family can be divided
into three main subclasses. The antiapoptotic proteins, which family and include BID, NOXA, PUMA, BIK, BIM, and BAD (Kele-
kar and Thompson, 1998). These proteins share sequence ho-include BCL-2 and BCL-XL, are all “multidomain,” sharing ho-
mology throughout all four BH domains. However, the proapo- mology only in the amphipathic -helical BH3 region, which
mutation analysis has indicated is required in proapoptoticptotic proteins can be further subdivided and include multido-
main proteins, such as BAX and BAK, which possess sequence members for their death activity. Moreover, the BH3-only pro-
teins require this domain in order to demonstrate binding tohomology in BH1-3 domains. The more distantly related “BH3-
only” proteins are to date all proapoptotic and share sequence multidomain BCL-2 family members. Multiple binding assays,
including yeast two-hybrid, coimmunoprecipitation from deter-homology within the amphipathic -helical BH3 region, which
is required for their apoptotic function (Chittenden et al., 1995; gent-solubilized cell lysates, and in vitro pull-down experiments,
indicate that individual BH3-only molecules display some selec-O’Connor et al., 1998; Wang et al., 1996; Zha et al., 1997).
Multidomain proapoptotic proteins such as BAX and BAK tivity for multidomain BCL-2 members (Boyd et al., 1995; O’Con-
nor et al., 1998; Oda et al., 2000; Wang et al., 1996; Yang etupon receipt of death signals participate in executing mitochon-
drial dysfunction. In viable cells, these proteins exist as mono- al., 1995). The BID protein binds proapoptotic BAX and BAK
as well as antiapoptotic BCL-2 and BCL-XL (Wang et al., 1996;mers. In response to a variety of death stimuli, however, inactive
S I G N I F I C A N C E
Cancer cells frequently and perhaps invariably possess aberrations in the genetic pathway of programmed cell death. The BCL-2
family of proteins constitutes a critical checkpoint in the apoptotic cascade. Cancer cells often demonstrate altered ratios of
antiapoptotic members (e.g., BCL-2) to proapoptotic members (e.g., BAX, BAK), which promotes survival and confers resistance to
therapy. We describe synthetic peptides that correspond to BH3 killing domains of prodeath members. Selected BH3 peptides initiate
cell death either by activating proapoptotic members or by counteracting antiapoptotic members, displacing BH3 domains from
their pockets. These tool compounds serve as prototypes for molecules that specifically target the abnormal cell death pathway of
cancer cells.
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Table 1. Peptide sequence, BCL-2 affinity, BID displacement, and -helicity
Kd (nM), BCL-2 IC50 (nM), BID % helicity
Amino acid sequence binding SD  displacement SD  (222 nM)
BIDBH3 EDIIRNIARHLAQVGDSMDR 220 30 838 192 19.5
BIMBH3 MRPEIWIAQELRRIGDEFNA 74 2 ND - 15.8
mBADBH3 LWAAQRYGRELRRMSDEFEGSFKGL 39 6 173 60 ND
BADBH3 NLWAAQRYGRELRRMSDEFVDSFKK 41 11 ND - 23.9
BIKBH3 MEGSDALALRLACIGDEMDV 485 272 4920 1648 8.5
NOXAABH3 AELPPEFAAQLRKIGDKVYC 1000 - 30,000 - 5.1
NOXABBH3 PADLKDECAQLRRIGDKVNL 1000 - 30,000 - 11.6
BCLXBH3 VIPMAAVKQALREAGDEFEL 1000 - 30,000 - 3.9
BIDBH3 mut EDIIRNIARHAAQVGASMDR 1000 - 30,000 - 16.4
BH3 peptide sequence were derived from human or mouse (m) where listed. NOXA has two BH3 domains, noted as A and B. Dissociation constants (Kd)
for binding of fluorescein-tagged peptides to GST-tagged BCL-2 protein were determined by fluorescence polarization. IC50 refers to the concentration
of unlabeled peptide required to displace 50% of the fluoresceinated BIDBH3 bound to 1 M GST-BCL-2. Percent -helicity in aqueous solution was
determined by circular dichroism.
Wei et al., 2000). In contrast, BAD, NOXA, and BIM as intact ptotic multidomain members to test if they function through a
single or distinguishable pathways. These studies indicate thatmolecules display preferential binding to antiapoptotic mem-
individual BH3 domains possess distinct functions. A BID-likebers (Boyd et al., 1995; O’Connor et al., 1998; Oda et al., 2000;
subset “activates” proapoptotic BAK, BAX, whereas a BAD-Yang et al., 1995). However, expression of all of these members
like subset occupies the pocket of antiapoptotic BCL-2, thus(BID, BAD, BIM, and NOXA) results in the activation of BAX and
“sensitizing” to the availability of other activating BH3 domains.BAK. Moreover, their expression in Bax, Bak doubly deficient
These peptides represent two classes of tool compounds thatcells indicates that BAX and BAK are absolutely required for
initiate cell death using genetically defined pathways.their induction of cell death (Cheng et al., 2001; Zong et al.,
2001). Comparison of wild-type (wt) versus mutant BCL-2,
ResultsBCL-XL indicated that antiapoptotic members sequester all of
these BH3-only molecules in stable mitochondrial complexes,
BH3 peptides from BID and BIM, but not all BH3-onlypreventing the activation of BAX and BAK (Cheng et al., 2001).
members, release cytochrome c similarHowever, these findings leave an important, yet unresolved is-
to myristoylated BIDsue as to whether BH3-only molecules function identically in a
Recombinant p15tBID, and even more efficiently the p7/myrp15,single pathway or whether two subsets exist based on their
myristoylated BID complex (myrBID), initiate BAK oligomeriza-binding preference.
tion and cytochrome c release in a mitochondrial in vitro systemThe proapoptotic activity of BH3-only molecules is appar-
that appears to recapitulate the mitochondrial pathway of apo-ently kept in check by either transcriptional control or posttrans-
ptosis in vivo. Since the proapoptotic activity of BID in vitro andlational modification. Of the BH3-only members, the activation
in vivo requires an intact BH3 domain, we tested the ability ofof BID is understood in the most detail. Surface Fas and TNFRI
peptides derived from this BH3 domain to initiate this activity.death receptor signaling results in caspase-8-mediated cleav-
A 20-mer of BIDBH3 (aa 80–99) at 10 M (Table 1) provedage within an unstructured loop of the inactive p22 BID (Li et
capable of initiating cytochrome c release, as did myrBID (Figureal., 1998; Luo et al., 1998). A newly exposed N-terminal glycine
1A). Next, we compared the activity of other BH3 domain pep-is N-myristoylated, and the p7/myrp15 BID complex displays
tides. While BIMBH3 (Table 1) demonstrated cytochrome c re-increased efficiency and selectivity for targeting the outer mito-
lease, peptides derived from other BH3-only members BAD,
chondrial membrane (Zha et al., 2000). Comparison of wt versus
BIK, and NOXA (Table 1) even at 100 M did not display this
mutant p15 tBID indicates that an intact BH3 domain is required activity (Figure 1B). A peptide derived from the BH3 domain of
for cytochrome c release, but not for targeting to the mitochon- antiapoptotic Bcl-XL did not cause cytochrome c release (Figuredria. Blocking antibodies to BAK and Bak-deficient mitochon- 1B). Circular dichroism studies indicate that while the relative
dria prepared from hepatocytes both indicate that mitochondrial -helical content of these peptides varies, the percent -helicity
BAK is necessary in order for tBID to trigger release of cyto- does not solely dictate the activity of the peptides. While NOX-
chrome c (Wei et al., 2000). Coimmunoprecipitation and protein AABH3 and BCL-XLBH3 have relatively low -helical content,
binding studies support the capacity of tBID and BAK to interact BADBH3 demonstrates the highest -helical content and is still
(Wei et al., 2000). Yet, it remained uncertain whether the BH3 inactive in this assay (Table 1). Likewise, a peptide derived from
domain itself from BID, or for that matter from any BH3-only the BH3 domain of BID, but containing substitutions (L90A,
member, could be responsible for directly binding and activating D95A) at two residues highly conserved throughout the family,
BAK, BAX. retained -helicity but did not cause cytochrome c release (Ta-
Consequently, we turned to synthetic BH3 peptides from ble 1, Figure 1B).
representative BH3-only molecules to test whether these do-
mains, when removed from the context of intact protein, can BAK is required for BH3 peptide-induced
activate BAK or BAX, perhaps analogous to ligand/receptor cytochrome c release
interactions. Peptides were selected from BH3-only members To test whether BH3 peptides work through an established
mitochondrial pathway of apoptosis, we examined whether theythat display selective binding to antiapoptotic versus proapo-
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Figure 1. BIDBH3, myrBID, and BIMBH3 induce cy-
tochrome c release from mitochondria
Mitochondria isolated from FL5.12 cell line were
incubated for 30 min at room temperature with
the indicated peptides, and release of cyto-
chrome c was quantitated by ELISA.
required the multidomain member BAK to be present. One hall- Peptides that induce cytochrome c release
induce BAK oligomerizationmark of cytochrome c release by native tBID is that it requires
Previous work demonstrated that the translocation of tBID tothe presence of multidomain BAK or BAX in intact cells or BAK
the mitochondrion results in allosteric conformational activationon purified mitochondria (Wei et al., 2000, 2001). Immunoblots
of BAK, which includes its homooligomerization followed by theof mitochondria isolated from the liver of Bak/ mice confirmed
release of cytochrome c (Wei et al., 2000). We find that thethat neither multidomain proapoptotic BAX nor BAK was present
BIDBH3 peptide (like tBID or the p7/myr15BID complex) induces(Figure 2). Moreover, there is no compensatory alteration in the
BAK oligomerization as detected with the crosslinker BMH (Fig-levels of antiapoptotic BCL-2 members in the absence of BAX
ure 4A). Moreover, there is a temporal relationship between BAKand/or BAK (not shown). Comparison of 100 M BIMBH3 or
oligomerization and the release of cytochrome c induced byBIDBH3 peptide on Bak/ versus Bak/ mitochondria indi-
BIDBH3 peptide (Figures 4A and 4B). While BIMBH3 also in-cated that BAK is required for the release of cytochrome c
duces BAK oligomerization, BADBH3 peptide, which lacks the(Figure 3). This requirement for BAK argues that these -helical
ability to cause cytochrome c release, is unable to induce BAK
BH3 peptides function through the genetic pathway of mito-
oligomerization (Figure 4C). We found that BIMBH3 and
chondrial apoptosis rather than by an autonomous permeabiliza-
BIDBH3, but not BADBH3, could also induce oligomerization
tion of membranes that nonspecifically damages mitochondria. of BAX in mitochondria isolated from cultured FL5.12 cells,
which contain both BAX and BAK (Figures 2 and 4C). Note that
while BIDBH3 induces more prominent crosslinking of BAK than
does BIMBH3, BIMBH3 induces more prominent crosslinking
of BAX than does BIDBH3. We tested a mutant BID peptide
BIDBH3mut (L90A, D95A), and it lacked the ability to induce
either cytochrome c release (Figure 1B) or BAX, BAK oligomer-
Figure 2. BAX and BAK expression in mitochondria isolated from mouse liver Figure 3. Cytochrome c release induced by BIMBH3 and BIDBH3 is depen-
dent on the presence of the multidomain proapoptotic BAKand FL5.12 cells
Anti-BAK Ab immunoblot reveals that BAK expression is greater in FL5.12 Mitochondria from wt and Bak/ liver were incubated for 40 min at room
temperature with the indicated concentrations of BIDBH3 and BIMBH3.mitochondria than in mitochondria from mouse liver. As expected, there is
no BAK expression in the mitochondria from Bak/ liver. BAX is present on There is no release of cytochrome c from Bak/ mitochondria. BIDBH3 was
more potent than BIMBH3 in causing cytochrome c release in the presenceFL5.12 mitochondria but is undetectable in liver mitochondria. Cytochrome
c reflects loading of mitochondrial proteins. of BAK.
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Figure 4. BAK and/or BAX oligomerization ac-
companies peptide-induced cytochrome c re-
lease
A: Wild-type liver mitochondria were treated with
100M BIDBH3 at room temperature for the times
indicated. Following incubation, reactions were
treated with the irreversible crosslinker BMH.
Twenty-five micrograms protein from each reac-
tion was separated using denaturing electro-
phoresis. Monomeric and multimerized BAK spe-
cies were detected by immunoblots following
SDS-PAGE. B: Wild-type liver mitochondria were
treated as in A, and cytochrome c release was
measured by ELISA. C: Mitochondria from FL5.12
cells were treated for 30 min with 100 M of indi-
cated peptides. BAK immunoblot demonstrates
BMH-crosslinked BAK oligomers. Markers 1, 2, 3,
and 4 correspond to size of monomer, dimer,
trimer, and tetramer as determined in prior stud-
ies (Wei et al., 2000, 2001). D: BAX immunoblot
demonstrate BMH-crosslinked BAX oligomers
(Gross et al., 1998) in same treated FL5.12 mito-
chondria as in C.
ization (Figure 4C). These results indicate that BIDBH3 and of myrBID (30 nM), while BIKBH3 shows significant, but less,
BIMBH3 peptides, like intact tBID protein, are capable of induc- potency (Figure 6A). The remaining BH3 peptides derived from
ing an allosteric change in mitochondrial-resident BAK or BAX, NOXA and BCL-XL did not demonstrate the capacity to over-
which includes their homooligomerization and subsequent re- come BCL-2 protection (Figure 6A). Since even 100 M BADBH3
lease of cytochrome c. in and of itself cannot activate BAK or release cytochrome c,
this suggests that BADBH3 sensitizes mitochondria to BIDBH3
BCL-2 inhibits mitochondrial release of cytochrome c or BIMBH3 by successfully competing with these peptides for
by BH3 peptides binding to BCL-2. At 100 M, BADBH3 was able to restore the
Mitochondria bearing protective levels of antiapoptotic BCL-2 cytochrome c release of BCL-2-overexpressing mitochondria
do not release cytochrome c following treatment with 25 ng
tBID in vitro, apparently because tBID is bound and sequestered
by BCL-2 in stable complexes that prevent tBID from activating
BAK (Cheng et al., 2001). Similarly, mitochondria with overex-
pressed BCL-2 proved resistant to 10 M BIDBH3, 1 M
BIMBH3, as well as 30 nM myrBID, failing to release cytochrome
c (Figure 5A). Furthermore, the presence of BCL-2 is coordinate
with the loss of BAK oligomerization following exposure to BH3
peptide, suggesting that BCL-2 inhibits upstream of BAK activa-
tion (Figure 5B). These findings support a model wherein a major
component of BCL-2’s role in inactivating tBID is to specifically
sequester the BH3 domain, thus preventing BH3 itself from
activating multidomain proapoptotic members.
BADBH3 binds BCL-2 and restores cytochrome c
release by BID
We tested BH3 peptides that lack the intrinsic ability to activate
BAK and cause cytochrome c release for their capacity to inter-
Figure 5. BCL-2 inhibits the release of cytochrome c and the oligomerizationfere with the antiapoptotic protection by BCL-2. We reasoned
of BAKthat this subset of BH3 peptides might occupy the hydrophobic
A: Mitochondria isolated from parental and BCL-2-overexpressing FL5.12pocket of BCL-2 and consequently displace proapoptotic
cells were treated for 30 min at room temperature as indicated and cyto-BIDBH3 or BIMBH3 peptides. The BADBH3 peptide most prom-
chrome c release quantitated by ELISA. B: Mitochondria from parental and
inently demonstrates the capacity to overcome BCL-2 protec- FL5.12-BCL-2 cells treated with 10 M BIDBH3, incubated with crosslinking
agent BMH, and SDS-PAGE and immunoblot for BAK.tion of mitochondria treated with a subliminal concentration
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Figure 6. BADBH3 enables cytochrome c release
by BIDBH3, BIMBH3, and myrBID by overcoming
the inhibitory effect of BCL-2
Mitochondria isolated from parental and FL5.12-
BCL-2 cells were treated for 30 min at room tem-
perature with (A) 30 nM myrBID complex or 30
M of the indicated peptides, or a combination
of 30 nM myrBID and 30 M peptide, and release
of cytochrome c measured. The indicated mito-
chondria were treated with a range of concen-
trations of (B) BIDBH3, (C) BIMBH3, and (D) myrBID,
with or without BADBH3 peptide. E: Dose re-
sponse of BADBH3 as well as BIKBH3 enabling
myrBID-induced release of cytochrome c from
mitochondria of FL5.12-BCL-2 cells.
in a dose-response fashion to BIDBH3 (Figure 6B) and BIMBH3 lated BID complex (p7/myrp15BID). Addition of 200 M
BADBH3 to BCL-2-overexpressing mitochondria markedly re-(Figure 6C) to levels observed for wt mitochondria. We also
observed an increase in the sensitivity of wt mitochondria stores their sensitivity to even 1 nM myrBID. These BADBH3-
treated mitochondria are more sensitive than wt mitochondria,treated with BADBH3. This would be expected, since the source
of wt mitochondria, FL5.12 cells, express some murine BCL-2. probably reflecting the capacity of BADBH3 to inhibit the endog-
enous murine BCL-2 and BCL-XL resident on the mitochondriaWe also noted that the restoration of cytochrome c release by
BADBH3 was accompanied by restoration of BAK oligomeriza- (Figure 6D). We next examined the dose-response range of
BADBH3, revealing that it had measurable activity at concentra-tion (not shown).
We next tested whether eliminating BCL-2 protection by tions as low as 1 M in inhibiting BCL-2 (Figure 6E) and enabling
cytochrome c release by myrBID. At 100 M, BIKBH3 can alsoBADBH3 would enable the more physiologic ligand, myristoy-
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Figure 7. BADBH3 efficiently displaces BIDBH3
from BCL-2 protein
A: Curves of BIDBH3 and BADBH3 fluoresceinated
peptides binding to GST-BCL-2 quantitated by
fluorescence polarization. One experiment rep-
resentative of three performed is shown. B: Red
line: fluorescein-tagged BIDBH3 (25 nM) was in-
cubated with GST-BCL-2 (1 M) for 20 min.
BADBH3 was then added at the indicated con-
centrations, and fluorescence polarization de-
termined. Loss of polarization indicates displace-
ment of BIDBH3 from GST-BCL-2. Black line:
fluorescein-tagged BADBH3 (25 nM) was incu-
bated with GST-BCL-2 (1 M) for 20 min. BIDBH3
was then added at the indicated concentra-
tions, and fluorescence polarization measured.
BADBH3 displaces BIDBH3 from BCL-2 with
roughly 2 logs greater efficiency than BIDBH3 dis-
places BADBH3. C: Schematic model of two
classes of BH3 domains. One class (“BID-like”)
can activate multidomain proapoptotics BAK
and BAX but are sequestered when antiapo-
ptotic BCL-2 is in excess of BAK (and BAX). “BAD-
like” BH3 domains lack the ability to activate BAK
but bind tightly to antiapoptotic BCL-2, thus free-
ing the BID-like BH3 domain to activate BAK (or
BAX) and induce the mitochondrial pathway of
apoptosis. To view an animated version of the
model in C, see http://www.cancercell.org/cgi/
content/full/2/3/183/DC1.
restore near-total cytochrome c release to mitochondria overex- or BIKBH3) to displace activating BH3 domains (e.g., BIDBH3
or BIMBH3) from the pocket of antiapoptotic BCL-2. Once free,pressing BCL-2, demonstrating a mechanism of action like
activating BH3 domains by this model would trigger BAK oligo-BADBH3, albeit at higher concentrations (Figure 6E). This re-
merization with subsequent cytochrome c release (Figure 7C).veals that short BADBH3 and BIKBH3 peptides can effectively
compete with the natural myrBID protein for binding BCL-2, thus
Transduced BADBH3 and BIDBH3 synergize in killingabrogating BCL-2’s antiapoptotic effect and enabling myrBID-
leukemic cellsinduced cytochrome c release.
We next explored whether we could trigger apoptosis of cancer
cells by transduction of such BH3 peptides. Prior studies utiliz-BADBH3 displaces BIDBH3 from BCL-2
ing internalization moieties including decanoic acid, anten-by fluorescence polarization analysis
nepedia (ANT), or HIV Tat have noted confounding issues ofTo directly test whether BADBH3 could displace BIDBH3 from
cellular and mitochondrial toxicity. For example, when we linkedBCL-2, we utilized fluorescence polarization analysis. BADBH3
various BH3 domains to a Tat 11-mer, both wt and mutantpeptide bound full-length BCL-2 with approximately 5-fold
transduced peptides rapidly killed cells. Moreover, many conju-greater affinity than BIDBH3 peptide (average of 41 versus 220
gates did not appear to work through the genetic pathway, asnM; Table 1, Figure 7A). Moreover, BADBH3 can efficiently dis-
they displayed no inhibition by BCL-2 and readily killed Bax,place prebound BIDBH3 peptide from BCL-2 (Figure 7B). How-
Bak doubly deficient cells (not shown). Linking a polyarginineever, to compete with prebound BIDBH3, an excess of BADBH3
(8 aa) stretch to our BH3 peptides appears more promising.
is required, despite the 5-fold greater affinity of BADBH3 for
Polyarginine tags have been shown to facilitate the transport of
BCL-2 in solution. This finding suggests that a conformational peptides across the plasma membrane (Rothbard et al., 2000).
change takes place in either BCL-2 and/or a BH3 peptide upon r8BIDBH3 was capable of killing Jurkat leukemic cells, whereas
binding. In contrast, BIDBH3 does not effectively displace r8BIDBH3mut was ineffective. Moreover, the addition of non-
BADBH3 from BCL-2. Testing the remaining peptides reveals toxic 10 M r8BADBH3 was able to sensitize Jurkat cells to
that those peptides that cause cytochrome c release by them- subliminal concentrations (10 M) of r8BIDBH3 (Figure 8). Both
selves (BIDBH3 and BIMBH3) or those that enable cytochrome r8BIDBH3 and r8BADBH3 failed to kill Bax, Bak doubly deficient
c release by counteracting BCL-2 (BADBH3 and BIKBH3) all cells. Thus, this appears to provide an initial proof of concept
bind to BCL-2 with affinities in the 50–500 nM range. BADBH3 experiment that sensitizing and activating BH3 domains will also
and BIKBH3 demonstrate the ability to displace BIDBH3 from synergize in vivo to initiate apoptosis of cancer cells.
the BCL-2 protein (Table 1). The remaining peptides (NOXABH3,
NOXABBH3, BCLXBH3, BIDBH3mut) that were unable to over- Discussion
come BCL-2 inhibition did not bind detectably to BCL-2 or
displace BIDBH3 from BCL-2 (Table 1). These results are consis- The use of synthetic peptides coupled with genetically defined
mitochondria indicate that the BH3 peptide domain itself, ex-tent with the capacity of sensitizing BH3 domains (e.g., BADBH3
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Figure 8. r8BADBH3 sensitizes Jurkat cells to
r8BIDBH3 killing
Peptides were synthesized with sequence identi-
cal to that found in Table 1 with the addition of
eight d-arginine residues at the amino terminus
followed by a glycine linker residue. Apoptotic
cells were detected by Annexin V staining. Re-
sults of an experiment representative of four simi-
lar experiments are shown.
cised from the context of an entire BH3-only molecule, can was able to bind antiapoptotic BCL-XL was it capable of promot-
ing death (Kelekar and Thompson, 1998). Yet, BAD, NOXA, andfunction as a specific death ligand. The activity of BH3 peptides
supports a ligand/receptor model in which “BID-like” BH3 do- BIK all require the multidomain proapoptotic BAX, BAK proteins
to kill as evidenced in Bax, Bak doubly deficient cells (Chengmains are sufficient to trigger allosteric conformational activa-
tion of BAX, BAK, their respective receptors. Activation by et al., 2001; Zong et al., 2001). The ability of BAD-like BH3
peptides to mediate a displacement reaction from the antiapo-BIDBH3 peptide was qualitatively indistinguishable from the
myrBID protein in that either requires BAK, results in BAK oligo- ptotic BCL-2 pocket provides a mechanism of action that would
accommodate all observations. The cooperating protein dis-merization followed by cytochrome c release, and can be bound
and sequestered by BCL-2 with resultant protection of BAK. placed from antiapoptotic pockets within intact cells would in-
clude, but not be restricted to, BID-like activating BH3-onlyThe synthetic peptides also indicate that BH3 regions are true
domains rather than merely conserved sequence motifs, as the members. While helping to resolve this issue, the analysis of the
BIMBH3 peptide proved provocative. Prior interaction assayspeptide domain itself has inherent functional activity. Compari-
son of various-helical peptides from BH3-only proteins reveals indicate that the intact BIM protein displays preferential binding
to antiapoptotic BCL-2, BCL-XL over proapoptotic BAX or BAK.evidence for two functional classes of BH3 domains. BID-like
domains activate multidomain proapoptotic BAX, BAK, whereas Previous reports testing the capacity of intact BIM protein to
release cytochrome c from mitochondria gave differing resultsBAD-like domains sensitize mitochondria for apoptosis by occu-
pying the pocket of antiapoptotic BCL-2. The latter displace (Li et al., 2001; Terradillos et al., 2002). Here, the isolated BIM
BH3 domain when removed from the context of the entire pro-BID-like domains, which even at subliminal levels can now initi-
ate cytochrome c release. This predicts that therapeutics that tein scored as BID-like, capable of activating BAX, BAK. Several
potential explanations can be envisioned. It is possible that themimic a BH3 domain, whether they be peptidomimetics or small
molecules, will be assignable to these functional classes and critical -helical face of the BH3 domain that recognizes BAX,
BAK may not be exposed in the intact BIM protein. Alternatively,should be classified utilizing the genetic and molecular reagents
defined here. it is conceivable that the standard protein interaction assays
used to measure binding may not reflect all of the conformationalFrom a therapeutic vantage point, BAD-like sensitizing BH3
mimetics would possess several attractive characteristics. They states of a native BIM molecule during cell death in vivo.
The mechanistic pathway to cytochrome c release formight be predicted to reset susceptibility of cells protected by
BCL-2 or BCL-XL, but would require a second apoptotic signal BIDBH3 peptide appears similar to native myrBID complex,
yet the efficiency of triggering release varies greatly. Near totalto initiate an activating BH3-only protein. This implies that as
a single agent, sensitizing mimetics might prove nontoxic, espe- release of cytochrome c from mitochondria requires 10 nM
myrBID complex, but 10 M BIDBH3 peptide. Myristoylationcially to normal cells. The need for a second signal provides
the opportunity to utilize cancer cell-selective pathways that increases the efficiency of BID targeting to mitochondria and
could conceivably help focus its location on the outer mitochon-could also spare normal cells.
Evidence here for a sensitizing subset of BAD-like BH3 pep- drial membrane (Lutter et al., 2001; Zha et al., 2000). It is also
possible that an integrated myrp15BID protein may more effec-tides provides an explanation for previous, apparent discrepan-
cies concerning the mechanism of action of these proteins. tively present the BH3 domain to the BAK pocket. Of note, the
sources of mitochondria vary in their response to individualMost BH3-only intact proteins including BAD, NOXA, and BIK
display a marked binding preference for antiapoptotic members BH3 domains. BIDBH3 is more potent than BIMBH3 for liver
mitochondria, whereas BIMBH3 is more effective on the FL5.12BCL-2, BCL-XL in interaction assays of yeast two-hybrid, pull-
down, or coimmunoprecipitation from detergent-solubilized ly- mitochondria. This may reflect the presence of BAX on FL5.12
but not liver mitochondria. The efficiency of oligomerization (Fig-sates (Boyd et al., 1995; Oda et al., 2000; Yang et al., 1995).
Moreover, mutational analysis suggested that only when BAD ure 4) supports a preference of BIDBH3 for BAK and BIMBH3
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steps, followed by two washes in isolation buffer. Mitochondria from FL5.12for BAX. A hypothesis that BIMBH3 prefers BAX would be con-
cells were isolated by cell disruption followed by differential centrifugationsistent with the finding that BIM functions upstream of BAX in
and washing as above. Cell disruption was performed either by a Kinematikaneuronal cell death following NGF deprivation (Putcha et al.,
Polytron homogenizer or by a combination of Dounce homogenization fol-2001). The binding affinity of individual BH3 domains for BCL-2
lowed by 6–10 expulsions through a 27-gauge needle.
members varies considerably (Figure 7; Sattler et al., 1997),
providing a measurement for selectivity. Assessment of BH3 Cytochrome c release
peptides by circular dichroism indicates that -helical content Mitochondria at a protein concentration of 0.5 mg/ml were treated at room
is not the sole determinant of differential binding affinity, nor of temperature in experimental buffer (125 mM KCl, 10 mM Tris-MOPS [pH
7.4], 5 mM glutamate, 2.5 mM malate, 1 mM KPO4, 10 M EGTA-Tris [pHthe ability to induce BAX, BAK oligomerization and cytochrome
7.4]). Percent release was quantitated using a colorimetric ELISA (MCTC0,c release. The specificity noted suggests a model in which
R&D Systems). In all experiments, treatments with DMSO were used as adistinct BH3 domains have select multidomain partners, which
control for solvent activity.provides a rationale for the large number of both BH3-only and
multidomain antiapoptotic members.
BMH crosslinking
Whether the BH3 domains of multidomain members can 1,6-bismaleimidohexane was obtained from Pierce (#22330). A 10 mM stock
initiate apoptosis is less certain. The BH3 domain isolated from solution in DMSO was added to treated mitochondrial suspensions at a 1:11
BCL-XL studied here showed no activity, while BH3 peptides dilution. Crosslinking took place for 30 min at room temperature, followed
from BAX have generated mixed results. Addition of a BH3 by centrifugation to pellet mitochondria. Pellets were dissolved in NuPAGE
loading buffer (Invitrogen).peptide from BAK to a Xenopus cell free system induced release
of cytochrome c and caspase activity, although the site of action
Binding assayswas unknown (Cosulich et al., 1997). Addition of BAXBH3 to
To determine Kd for peptide binding to BCL-2, a GST-BCL-2 fusion proteinmammalian mitochondria has been reported to release cyto-
lacking the C-terminal transmembrane domain was utilized. Peptides were
chrome c without inducing permeability transition (Polster et al.,
synthesized with a fluorescein amino terminus using an AHA linker. Peptides
2001), consistent with the mechanistic pathway dissected here, at 25 nM were mixed with titrations of GST-BCL-2 in binding buffer (140 mM
whereas others report BAXBH3 peptides that do induce perme- NaCl, 10 mM Tris [pH 7.4]) at 37C. An increase in fluorescence polarization
ability transition and loss of transmembrane potential as an measured on a Perkin-Elmer LS 50B luminescence spectrophotometer was
quantitated to calculate binding. A nonlinear fit to a sigmoidal dose-responseexplanation for cytochrome c release (Narita et al., 1998). This
curve utilized the program Origin 6.0 to determine Kd. For quantitativemay be inherent to  helices themselves or to hybrid proteins
BIDBH3 displacement assays, 25 nM fluoresceinated BIDBH3 was mixedthat can damage organelle membranes.
with 1 M GST-BCL-2 in binding buffer. Increasing amounts of unlabeledA substantial challenge for the future is to effectively trans-
BH3 peptides were titrated in, with loss of fluorescence polarization as aduce BH3 peptides or BH3 peptidomimetics into cells and as-
measurement of displacement of BIDBH3. Data were fitted to a sigmoidal
sure that the induction of apoptosis is through the genetic path- curve as above, and IC50 determined.
way. Several studies (Holinger et al., 1999; Wang et al., 2000)
including the initial polyarginine transduction approach pre- GST-BCL-2 production
sented here suggest this warrants further efforts. However, cau- GST-BCL-2 C21 fusion proteins were induced in BL21 DE3 by 0.1 mM
IPTG. The bacterial pellets were resuspended in lysis buffer (1 mg/ml lyso-tion exists as a number of amphipathic -helical peptides, espe-
zyme, 1% Triton X-100, 0.1 mg/ml PMSF, 2 g/ml aprotinin, 2 g/ml leupep-cially if they are cationic, can be attracted to negatively charged
tine, 1 g/ml pepstatin A in PBS) and sonicated. After centrifugation atmembranes, including mitochondrial membranes, where they
20,000 	 g for 20 min, the supernatant was applied to glutathione-agarosecan nonspecifically disrupt the lipid matrix and membrane bar-
beads (Sigma). The beads were washed with PBS and treated with 50 mM
rier function (Ellerby et al., 1999; Matsuzaki, 2001; Westerhoff
glutathione, 50 mM Tris-HCl (pH 8.0) to elute protein. Eluate was dialyzed
et al., 1989). Others utilizing ANT-BH3BAD found toxicity was against binding buffer and concentrated using Amicon centrifugal concen-
independent of the BCL-2 pathway and also killed yeast, which trating devices.
tolerate expression of the BH3-only proteins (Schimmer et al.,
2001; Vieira et al., 2002). Alternative methods of internalization Circular dichroism
Circular dichroism (CD) spectra were obtained on a Jasco J-710 spectropo-including receptor-mediated pathways should also be consid-
larimeter at 20C using the following standard measurement parameters:ered for BH3 peptidomimetics. The work here provides a proof
wavelength, 190–260 nm; step resolution, 0.5 nm; speed, 20 nm/sec; accu-of concept that BH3 mimetics can be designed that initiate
mulations, 10; response, 1 s; band width, 1 nm; path length, 0.1 cm. Stockapoptosis correctly, at definable points in the genetic pathway.
solutions of peptide were dissolved in deionized water and concentrationsMoreover, it provides a paradigm and reagents to dissect the
determined by amino acid analysis. Samples were then diluted in 50 mM
mechanism of action of future BH3 mimetics. potassium phosphate (pH 7) to a calculated final concentration of 50M. The
CD spectrum of each sample was measured in triplicate and a background
Experimental procedures
spectrum of diluent alone was subtracted. For comparison, the subtracted
CD spectra were normalized to 35M based on repeat peptide concentration
Peptide stocks
determination by amino acid analysis of the diluted peptide solutions. ThePeptides were synthesized by Tufts University Core Facility and purified by
-helical content of each peptide was calculated by dividing the mean resi-HPLC, and identity was confirmed by mass spectroscopy. Stock solutions
due ellipticity [q]222obs by the reported [q]222obs for a model helical deca-were 10–20 mM DMSO.
peptide (Yang et al., 1986).
Isolation of mitochondria
Immunoblot analysisMouse liver mitochondria were isolated from age-matched wt or Bak/
Antibodies used for immunoblot analysis included anti-cytochrome cmice. Livers were diced, subjected to Dounce rotary Teflon pestle disruption,
(75981A, Pharmingen), anti-BAK (Upstate Biotechnology), and anti-BAXand then homogenized using a Kinematica Polytron homognizer. Following
(N-20, Santa Cruz). Antibody detection was accomplished using enhancedsuspension in isolation buffer (250 mM sucrose, 10 mM Tris-HCl [pH 7.4],
0.1 mM EGTA), mitochondria were isolated by differential centrifugation chemiluminescence (Western Lightning, Perkin-Elmer).
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Bcl2 interacting protein, mediates cytochrome c release from mitochondriaJurkat cell death experiments
in response to activation of cell surface death receptors. Cell 94, 481–490.Jurkat cells were grown in RPMI 1640, 10% fetal bovine serum, 100 U/ml
penicillin, 100 g/ml/strep, 2 mM glutamine, 50 M 
-mercaptoethanol.
Lutter, M., Perkins, G.A., and Wang, X. (2001). The pro-apoptotic Bcl-2
Cells were treated with peptide for 5 hr followed by staining with fluores- family member tBid localizes to mitochondrial contact sites. BMC Cell Biol.
cently-tagged Annexin V according to manufacturer’s protocol (BD Biosci- 2, 22.
ences 556547). Death was quantitated by FACS, followed by analysis using
Matsuzaki, K. (2001). Why and how are peptide-lipid interactions utilized forFlowJo software (Tree Star, Inc.).
self defence? Biochem. Soc. Trans. 29, 598–601.
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